Stockscreener 앱 받기
22.03
1.94%
0.42
시간 외 거래:
22.03
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - Barchart.com
Glioblastoma Pipeline 2025: Therapies Under Investigation, - openPR.com
Can ACADIA Pharmaceuticals Inc. stock sustain institutional interestCEO Change & Weekly High Potential Alerts - mfd.ru
Understanding Momentum Shifts in (ACAD) - Stock Traders Daily
ACADIA’s ACP-211 Trial Targets Difficult-to-Treat Depression: What Investors Should Watch - TipRanks
Can ACADIA Pharmaceuticals Inc. sustain its profitabilityLayoff News & Verified Momentum Watchlists - mfd.ru
Candriam S.C.A. Buys New Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 6,950 Shares of Stock - MarketBeat
ACADIA Pharmaceuticals Inc. (ACAD): Investor Outlook Reveals 34% Upside Potential Amid Robust CNS Pipeline - DirectorsTalk Interviews
ACADIA Pharmaceuticals: Biotech Optimism Meets Volatile Reality After A Sharp Pullback - AD HOC NEWS
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shares Lagging The Market But So Is The Business - 富途牛牛
ACAD: Oppenheimer Raises Price Target to $23, Maintains Rating | - GuruFocus
Oppenheimer Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Acadia Pharmaceuticals stock price target raised to $23 from $21 at Oppenheimer - Investing.com Canada
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug EndMonth: How do insiders feel about ACADIA Pharmaceuticals IncEarnings Risk Report & Capital Protection Trading Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals (ACAD) Is Down 5.5% After EMA Trend Vote Goes Against Daybue In Europe - Sahm
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire
European regulators unlikely to recommend approval of Daybue - Rett Syndrome News
Analysts Are Bullish on Top Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Acadia Pharmaceuticals Shares Drop After Phase 3 PWS Trial Misses Primary Goal - MSN
A Glimpse Into The Expert Outlook On ACADIA Pharmaceuticals Through 11 Analysts - Benzinga
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $31 - 富途牛牛
EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug - Benzinga
ACAD Maintains Outperform Rating Despite Lowered Price Target | - GuruFocus
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says - marketscreener.com
Acadia Pharmaceuticals stock price target lowered to $31 at RBC Capital - Investing.com Canada
EU Not The Land Of Plenty For Acadia After Rett Therapy Snub - Citeline News & Insights
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
ACADIA Pharmaceuticals (ACAD) Analyst Rating Reaffirmed by Citiz - GuruFocus
Citizens Jmp Reiterates Market Outperform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) - MarketBeat
ACAD: HC Wainwright & Co. Reiterates Buy Rating with $37 Target - GuruFocus
Acadia Pharmaceuticals stock faces EMA hurdle for Rett syndrome drug By Investing.com - Investing.com Canada
Acadia Pharmaceuticals stock faces setback as CHMP signals negative vote By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) - MarketBeat
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - Eastern Progress
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union - BioSpace
The Bull Case For ACADIA Pharmaceuticals (ACAD) Could Change Following EMA Setback For Trofinetide Approval - Yahoo Finance
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Strong One Year Share Price Gain? - Sahm
CHMP signals negative stance on Acadia's Rett syndrome drug ahead of opinion - firstwordpharma.com
Acadia Faces EMA Setback On Rett Drug As Regulatory Test Looms - Yahoo Finance
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug By Investing.com - Investing.com South Africa
Is It Too Late To Consider ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Rebound? - Yahoo Finance
Acadia faces setback in EU approval for Rett syndrome treatment By Investing.com - Investing.com India
Neuren Faces EU Setback as EMA Panel Issues Negative Trend Vote on Trofinetide for Rett Syndrome - TipRanks
Acadia Pharmaceuticals Provides Update on Regulatory Submission f - The National Law Review
Acadia Pharma down after negative EU trend vote on neurological disorder drug - TradingView
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug - Investing.com
Acadia Pharmaceuticals Submits Marketing Authorization Application for Trofinetide to European Medicines Agency - geneonline.com
Why Did ACAD Stock Slump 8% After Hours Today? - Stocktwits
Acadia faces setback in EU approval for Rett syndrome treatment - Investing.com
Acadia Pharmaceuticals (ACAD) Encounters Hurdle in EU Approval f - GuruFocus
Acadia Pharmaceuticals provides update on regulatory submission for trofinetide for the treatment of Rett syndrome in the European Union - marketscreener.com
Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again - Finviz
Universal Beteiligungs und Servicegesellschaft mbH Lowers Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Privium Fund Management B.V. Sells 78,000 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Great Lakes Advisors LLC Sells 333,245 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
1.12%
0.87%
자본화:
|
볼륨(24시간):